Alnylam Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.05.25	Alnylam : Phase 3 HELIOS-B Study Shows Vutrisiran Reduces Cardiovascular Events In ATTR-CM (RTTNews)
09.03.23	Alnylam Pharma To Extend Its Existing Relationship With Medison (RTTNews)
09.03.23	Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics (PR Newswire)
23.02.23	Alnylam Pharmaceuticals Inc. Q4 Loss Decreases, beats estimates (RTTNews)
21.02.23	Alnylam Pharma : FDA Accepts SNDA For Patisiran For Treatment Of Cardiomyopathy Of ATTR Amyloidosis (RTTNews)
01.05.19	Alnylam Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates (RTTNews)
27.07.15	Alnylam Pharma Initiates Phase 1/2 Clinical Trial With ALN-AAT - Quick Facts (RTTNews)
12.12.14	Alnylam Pharma Announces Pipeline Growth Strategy For RNAi Therapeutics (RTTNews)
14.11.14	Alnylam Pharma Announces Positive Initial Phase 2 Data With Revusiran (RTTNews)
14.10.14	Tekmira's Partner Announces Positive Clinical Data For LNP-Enabled Patisiran (RTTNews)
13.10.14	Alnylam Announces Data From Patisiran Phase 2 OLE Study In Patients With FAP (RTTNews)
07.08.14	Alnylam Gets Orphan Drug Designations In European Union For ALN-AT3 (RTTNews)
11.05.14	Alnylam Pharma Presents Key Scientific Data On ESC-GalNAc-Conjugate Technology (RTTNews)
08.05.14	Alnylam Pharma Q1 Loss Widens - Quick Facts (RTTNews)
14.02.14	Alnylam Pharma Q4 Loss Narrowed - Quick Facts (RTTNews)
14.01.14	Isis To Receive $7.5 Mln From Alnylam-Genzyme Alliance (RTTNews)
13.01.14	Genzyme Expands Alliance With Alnylam Pharma, To Invest $700 Mln For 12% Stake (RTTNews)
13.01.14	Alnylam Pharma, Genzyme Form New RNAi Therapeutics Alliance - Quick Facts (RTTNews)
13.01.14	Alnylam Pharma To Buy Merck's Wholly Owned Subsidiary Sirna Therapeutics (RTTNews)
13.01.14	ALNY Opens Wallet, MNKD Gets FDA Panel Date, STEM Keeps Growing (RTTNews)
16.12.13	Alnylam Pharma Begins Pilot Phase II Study With ALN-TTRsc (RTTNews)
09.12.13	Alnylam Presents New Pre-clinical Data On ALN-CC5 - Quick Facts (RTTNews)
25.11.13	Alnylam Earns $7 Mln Milestone Payment From Genzyme On Patisiran Achievement (RTTNews)
11.11.13	Alnylam Gets Fast Track Status For Patisiran To Treat ATTR Patients With FAP (RTTNews)
15.10.13	Upcoming Financial Results Schedules, Clinical Studies and Trials, and New Appointments - Research Report on BioMarin, Alnylam, Aegerion, Omeros, and Tesaro (PR Newswire)
07.10.13	Clinical Study Updates, Trial Enrollments, NDA Submissions, Partnerships, and Formation of New Subsidiaries - Research Report on BioMarin, Alnylam, Vertex, Illumina, and Intrexon (PR Newswire)
03.10.13	Alnylam: ALN-PCS Phase I Study Results Published In The Lancet (RTTNews)
01.10.13	ACRX Files Zalviso NDA, BGMD Gets A Booster, UK's NICE Turns Nice To PSDV (RTTNews)
30.09.13	Alnylam Pharma Completes Enrollment Of Phase II Clinical Trial With ALN-TTR02 (RTTNews)
26.09.13	Application for Regulatory Approvals, Conferences and Presentations, and Enrollment in Clinical Trials - Research Report on Gilead, Alnylam, Omeros, PTC, and Stemline (PR Newswire)
23.09.13	Alnylam Reports Positive Interim Results From Phase I Trial Of ALN-TTRsc (RTTNews)
03.09.13	Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals (PR Newswire)
26.08.13	Positive Clinical Trial Results, Regulatory Wins, and New Appointments - Research Report on Incyte, Edwards, ACADIA Pharmaceuticals, Alnylam, and Ironwood (PR Newswire)
20.08.13	Alnylam Pharma Gets Addl. Orphan Drug Designation For ALN-AT3 For Hemophilia A (RTTNews)
15.08.13	Pharma Companies Announce Investments in R&D, Ongoing Clinical Trials and Financial Results - Research Report on Alnylam, Infinity, Nektar, Sequenom, and Merrimack (PR Newswire)
15.08.13	SPRING Makes AMPE Jump, AVNR Buys Peace, FRX Delays NDA Submission (RTTNews)
14.08.13	Alnylam Pharma's ALN-AT3 Granted Orphan Drug Status By FDA - Quick Facts (RTTNews)
08.08.13	Alnylam Pharma. Q2 Loss Widens - Quick Facts (RTTNews)
15.07.13	Alnylam - Silent No More (RTTNews)
11.07.13	RMTI Cruises Ahead, ALNY, CELG Touch New Highs, BIOD Progresses (RTTNews)
11.07.13	Pre-market Movers For July 11 (APOL, CELG, ALNY, GOLD, QLIK, DRWI, RMTI) (RTTNews)
11.07.13	Alnylam Reports Positive Top-line Results From Ongoing ALN-TTRsc Phase I Trial (RTTNews)
23.03.10	Alnylam Completes Key Technology Transfer Objectives in its Takeda Alliance and Earns $20 Million Payment (Businesswire)
18.02.10	Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2009 Financial Results (Businesswire)
08.01.10	Alnylam and Collaborators Discover Key Mechanism for Delivery of RNAi Therapeutics (Businesswire)
29.12.09	Alnylam and Collaborators at MIT Report New Pre-clinical Research on Systemic Delivery of RNAi Therapeutics (Businesswire)
05.11.09	Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) Meeting (Businesswire)
29.10.09	Alnylam to Participate in Major Cardiovascular Disease Research Grant Awarded to Scientists at University of Pennsylvania (Businesswire)
06.08.09	Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results (Businesswire)
19.12.08	Alnylam Publishes Pre-Clinical Research on Direct CNS Delivery of RNAi Therapeutics (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	611.00	0.79 %	K V
Swisscom	568.00	0.18 %	K V
Sika	222.50	-0.18 %	K V
Holcim	94.56	-0.30 %	K V
UBS Group	26.42	-0.38 %	K V
Logitech Intl	70.14	-0.93 %	K V
Alcon	71.24	-1.00 %	K V
Swiss Re	146.75	-1.05 %	K V
Kuehne+Nagel Int	186.85	-1.09 %	K V
Sonova Hldg	259.40	-1.41 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Alnylam Pharmaceuticals Aktie VALOR 1806798 / ISIN US02043Q1076

Nachrichten zu Alnylam Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten